Immunic CEO Buys $11.5K Shares, Receives 1.56M Stock Options

Immunic CEO Daniel Vitt filed an amended Form 4 on June 28, 2025, correcting a previously filed Form 4 from June 6, 2025.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

4/A

Rhea-AI Filing Summary

Immunic CEO Daniel Vitt filed an amended Form 4 on June 28, 2025, correcting a previously filed Form 4 from June 6, 2025. The amendment addresses two significant transactions:

Stock Purchase: Acquired 15,000 shares of common stock at $0.77 per share on June 4, 2025, bringing direct ownership to 29,000 shares
Stock Option Grant: Received 1,558,000 stock options on June 5, 2025, with an exercise price of $0.7729, expiring June 5, 2035

The options vest 25% after one year, with remaining shares vesting monthly over 36 months. Vitt also maintains indirect ownership of 362,877 shares through Listrax UG, where he serves as Managing Director. The amendment specifically corrects an administrative error regarding the number of stock options granted in the original filing.

Positive

CEO Daniel Vitt made a direct open market purchase of 15,000 shares at $0.77 per share, demonstrating insider confidence
CEO received a significant stock option grant of 1,558,000 shares at $0.7729, aligning long-term interests with shareholders

Negative

None.

Insider Trade Summary

Net Buyer: 15,000 shares

Net Buy 3 txns

Insider Vitt Daniel

Role CEO and Director

Bought 15,000 shs ($12K)

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	1,558,000	$0.00	$0.00
Purchase	Common Stock	15,000	$0.77	$12K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option — 1,558,000 contracts (Direct); Common Stock — 29,000 shares (Direct); Common Stock — 362,877 shares (Indirect, See footnote)

Footnotes (3)

F1. The purchase was made in Euros and the price was converted into U.S. dollars based on the foreign currency exchange rate as of June 4, 2025 (at Euro 1.00 = U.S. dollar 1.1384).
F2. 362,877 shares of the Issuer's common stock are owned by Listrax UG (haftungsbeschrankt). The RP is Managing Director of Listrax UG and exercises voting and dispositive power over such shares.
F3. 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IMUX shares did CEO Daniel Vitt purchase on June 4, 2025?

CEO Daniel Vitt purchased 15,000 shares of IMUX common stock at a price of $0.77 per share on June 4, 2025. The purchase was made in Euros and converted to USD at an exchange rate of 1 Euro = $1.1384.

What stock options were granted to IMUX's CEO in June 2025?

On June 5, 2025, Daniel Vitt was granted 1,558,000 stock options with an exercise price of $0.7729. The options vest 25% after one year, with the remainder vesting in equal monthly increments over the following 36 months. The options expire on June 5, 2035.

What is the total IMUX stock ownership of CEO Daniel Vitt after the reported transactions?

Following the reported transactions, Daniel Vitt directly owns 29,000 shares of IMUX common stock and indirectly controls 362,877 shares through Listrax UG (where he serves as Managing Director). He also holds 1,558,000 stock options.

Why did IMUX file a Form 4/A amendment on June 28, 2025?

IMUX filed the Form 4/A to amend the original Form 4 filed on June 6, 2025, correcting an administrative error that incorrectly reported the number of stock options granted to CEO Daniel Vitt.

What indirect ownership of IMUX stock does Daniel Vitt have?

Daniel Vitt indirectly owns 362,877 shares of IMUX common stock through Listrax UG (haftungsbeschrankt), where he serves as Managing Director and exercises voting and dispositive power over the shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/20/2025 - 05:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vitt Daniel

(Last)

(First)

(Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK

10036

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO and Director

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/06/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/04/2025		P		15,000	A	$0.77⁽¹⁾	29,000	D
Common Stock								362,877	I	See footnote⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$0.7729	06/05/2025		A		1,558,000		⁽³⁾	06/05/2035	Common Stock	1,558,000	$0.00	1,558,000	D

Explanation of Responses:

1. The purchase was made in Euros and the price was converted into U.S. dollars based on the foreign currency exchange rate as of June 4, 2025 (at Euro 1.00 = U.S. dollar 1.1384).

2. 362,877 shares of the Issuer's common stock are owned by Listrax UG (haftungsbeschrankt). The RP is Managing Director of Listrax UG and exercises voting and dispositive power over such shares.

3. 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.

Remarks:

This Form 4/A is being filed to amend the prior Form 4 filed by the Reporting Peron on June 6, 2025 to correct an administrative error that incorrectly reported the number of stock options granted.

	/s/ Daniel Vitt	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR